- Home
- ATOS vs KNDI Comparison
ATOS vs KNDI Comparison
Compare ATOS & KNDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- KNDI
- Stock Information
- Founded
- ATOS 2009
- KNDI 2002
- Country
- ATOS United States
- KNDI China
- Employees
- ATOS N/A
- KNDI N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- KNDI Auto Manufacturing
- Sector
- ATOS Health Care
- KNDI Consumer Discretionary
- Exchange
- ATOS Nasdaq
- KNDI Nasdaq
- Market Cap
- ATOS 96.8M
- KNDI 112.8M
- IPO Year
- ATOS 2012
- KNDI N/A
- Fundamental
- Price
- ATOS $0.74
- KNDI $1.18
- Analyst Decision
- ATOS Strong Buy
- KNDI
- Analyst Count
- ATOS 3
- KNDI 0
- Target Price
- ATOS $7.13
- KNDI N/A
- AVG Volume (30 Days)
- ATOS 714.9K
- KNDI 131.0K
- Earning Date
- ATOS 05-12-2025
- KNDI 05-15-2025
- Dividend Yield
- ATOS N/A
- KNDI N/A
- EPS Growth
- ATOS N/A
- KNDI N/A
- EPS
- ATOS N/A
- KNDI N/A
- Revenue
- ATOS N/A
- KNDI $118,127,232.00
- Revenue This Year
- ATOS N/A
- KNDI N/A
- Revenue Next Year
- ATOS N/A
- KNDI N/A
- P/E Ratio
- ATOS N/A
- KNDI N/A
- Revenue Growth
- ATOS N/A
- KNDI N/A
- 52 Week Low
- ATOS $0.55
- KNDI $0.89
- 52 Week High
- ATOS $1.81
- KNDI $2.72
- Technical
- Relative Strength Index (RSI)
- ATOS 58.85
- KNDI 42.09
- Support Level
- ATOS $0.59
- KNDI $1.09
- Resistance Level
- ATOS $0.67
- KNDI $1.27
- Average True Range (ATR)
- ATOS 0.06
- KNDI 0.09
- MACD
- ATOS 0.01
- KNDI -0.01
- Stochastic Oscillator
- ATOS 88.47
- KNDI 34.62
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About KNDI Kandi Technologies Group Inc
Kandi Technologies Group Inc is engaged in the development, production, and distribution of electric vehicle (EV) products, EV parts, and off-road vehicle products in the Chinese market. Other product offerings include all-terrain vehicles, go-karts, utility vehicles, battery packs, and other systems. It generates maximum revenue through off-road vehicles. The company generates the majority of its revenue from the United states along with other Countries, followed by China.